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Leo Timms, Associate Professor of Animal Science, and
Phil Sears, Professor of Veterinary Clinical Medicine,
Michigan State University
Summary and Implications
One objective of this field investigation was to evaluate
the efficacy of extended therapy with pirlimycin
hydrochloride with or without vaccination prior and during
therapy for S. aureus mastitis. 80% of cows and 44% of
quarters were infected with S. aureus.  S. aureus infected
animals were split into 3 groups with all quarters of all cows
treated with extended pirlimycin therapy. One group
received a vaccine which had herd autogenous strains (AV),
and another group received a new trivalent S. aureus
vaccine (TV) at 14 and 1.5 days prior to treatment, and 6
days after treatment started. Cure rates at 32 days post
treatment were 18%, 38%, and 56% for treatment only
(TO), (AV), and (TV) groups. Cure rates at 60 days post
treatment were 14%, 33%, and 33%, respectively when all
cows were included in the analysis, and 14, 17, and 14%,
respectively, when high SCC quarters with no 60 day data
were excluded from the analysis. Coupling vaccination to
extended therapy was not successful in this herd ( compared
to other data) possibly due to underlying herd nutrition
problems. This study also points out that bacteriological
cure must be assessed later (>30-45 days post treatment)
and / or quarter SCC should be used when multiple therapy
strategies are coupled together.
Introduction
The objectives of this field investigation were to 1)
examine mastitis infection dynamics in a herd whose normal
herd bulk tank SCC was 400,000 cells/ml but had jumped
over 1 million for 2-3 months from Jan.-March; 2)
investigate herd management and procedures and develop
and prioritize necessary changes for mastitis prevention; and
3) evaluate the efficacy of extended therapy with pirlimycin
hydrochloride (Pirsue, Pharmacia/Upjohn., Kalamazoo, MI.)
with or without vaccination prior and during therapy for
Staphylococcus aureus mastitis.
Materials and Methods
The herd (40 Jersey cows) involved in this field trial
was in danger of market loss due to high SCC. The normal
SCC for the herd was ~ 400,000 (culled 3-6 chronic
cows/year to maintain this), but had jumped to > 1 million
in January following a day where animals were exposed for
12 hours to sub-zero wind chills (cows exclusively inside all
winter usually) due to water problems in the barn. During
the initial visit, milking equipment and procedures were
evaluated. All cows were CMT’d with aseptic milk samples
taken from quarters that were CMT > 1, and composite milk
samples were collected for subsequent SCC analysis.  Initial
herd visit information showed cows with a 16 kg/day milk
average, in good body condition, and both animals and barn
facilities very clean. Animals were housed in a 3 row
stanchion barn and milked in a bucket or floor pail milking
system utilizing 3 units. Premilking sanitation consisted of
washing teats using water with iodine udder wash using a
common rag, no drying, and some forestripping although
milk was not being evaluated closely. Producer was milking
problem cows last but poor visual appraisal meant many
were being missed. Teats were dipped post milking with a
germicidal teat dip but coverage was only fair.
Approximately 25% of cows were showing clinical mastitis
signs on initial sampling. Initial aseptic quarter samples
from 30 cows showed that 80% of cows and 44% of
quarters were infected with S. aureus.  Milking equipment
analysis revealed adequate pump capacity, poor regulator
performance (spring loaded regulator), 2 of 3 pulsators not
functioning properly, high teat end vacuum (14.2”), and a
leak in a seal on the receiver for the milk vacuum transfer
system. DHIA data also showed milk urea nitrogen to be
very low (< 5 mg/dl) indicating animals being protein
starved or deficient. Ration analysis showed that the
producer cut back all protein supplements when milk
production had dropped and protein from the sole forage
source (hay) was not sufficient to meet protein demands.
Strategies for preventing new IMI were categorized as
immediate (pulsators/ regulator/ teatdip/milking procedures/
better clinical observation), short (nutrition strategies), or
long term (heifer evaluation), discussed, and implemented.
S. aureus infected animals were split into 3 groups, with an
attempt to balance the number of infected cows/quarters in
each group as well as age and stage of lactation. Quarter
milk samples for bacteriology, SCC, and other milk
components were taken 3 times prior to treatment and at 14,
32, and 60 days post treatment. All quarters of all cows were
treated with pirlimycin ( 2 total tubes 24 hrs apart, repeated
3 times, with 48 hrs in between treatment series). One group
received a vaccine which had herd autogenous strains
incorporated, and another group received a new trivalent S.
aureus vaccine (Dr. Phil Sears- Michigan State Univ.) Cows
were vaccinated in the supramammary lymph node area at
14 and 1.5 days prior to treatment, and 6 days after
treatment started. All cows received 5 cc Vital E on
vaccination days.  Blood and milk samples were also
collected at the beginning, end and 3 times during the trial
for antibody analysis.
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Results and Discussion
Cows/quarters with S. aureus in the treatment only
(TO), autogenous vaccine (AV), and trivalent vaccine (TV)
groups were 11/22, 10/21, and 7/18 cows respectfully. Cure
rates at 32 and 60 days post treatment are shown in Table 1.
Cure rates at 32 days post treatment were 18%, 38%, and
56% for TO, AV, and TV respectively. However, quarter
SCC of many cured quarters, especially vaccinated cows,
was still high at this time. Cure rates at 60 days post
treatment were 14%, 33%, and 33%, respectively when all
cows were included in the analysis. Some cows had been
dried off or sold so data on 6 vaccinated cows could not be
obtained at 60 days, so their 30 day cure rate data was used
even though 30 day quarter SCC was high on many of these
quarters.  If these high SCC quarters with no 60 day data are
excluded from the analysis, 60 day cure rates were 14, 17,
and 14%, respectively. Cure rates for all treatments were
low compared to other studies. During the trial, milk
component analysis showed low milk urea nitrogen across
the herd, indicating some protein starving and nutrition
problems. This probably played a major role in decreased
immunity and ability to cure infections. The data also bear
out that sampling cows at 30 days post treatment when both
treatment and vaccination are coupled may not be sufficient
time to assess true bacterial cure. Potentially waiting until
60 days or using quarter SCC was a better cure indicator.
Table 1. Staphylococcus aureus cure rates for cows receiving pirlimycin extended therapy with
              or without adjunct vaccination for Staphylococcus aureus
                                                                               Quarter cure rates  (%)                          .
                   Group                                         32 days                     60 days
                      TO                                             18%                           14%
                      AV                                             38% *                        33%** (17%)***
                      TV                                             56%*                         33%** (14%)***
TO = extended pirlimycin therapy only (EPT);    AV = EPT + autogenous vaccine;
TV = EPT + trivalent vaccine
*     high % of cured quarters with SCC > 500,000 cells/ml
**   6 vaccinated cows culled/dried off so 30 day cure rates used for those cows/quarters
*** Quarter data from 6 vaccinated cows culled/dried off before 60 days post trt. excluded
